⌕
BridgeBio Pharma · BBIO · Nasdaq
Tenet 43 · Weak
Compare
$76.80−0.72%At closeTenet 43 · Weak
$76.80−0.56 (−0.72%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

BridgeBio Pharma (BBIO) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is BBIO's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● GlobeNewsWireNov 17, 2026 · 07:30 ET
Acoramidis Was Associated with Lower Risk of Worsening Heart Failure Versus Tafamidis in Real-World Study and Reduced Heart Failure Events Within One Month in ATTRibute-CM

PALO ALTO, Calif., Nov. 17, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for g…

BBIO −0.7% todayRead at source ↗
● Seeking AlphaNov 16, 2026 · 07:42 ET
BridgeBio Pharma, Inc. (BBIO) Presents at Jefferies Global Healthcare Conference 2026 Transcript

BridgeBio Pharma, Inc. (BBIO) Presents at Jefferies Global Healthcare Conference 2026 Transcript…

BBIO −0.7% todayRead at source ↗
● GlobeNewsWireNov 11, 2026 · 07:30 ETCOMPANY'S OWN WORDS
BridgeBio to Present New Acoramidis Data on Kidney Function, Real-World Outcomes, and First-Line Treatment Patterns in ATTR-CM at the International Symposium on Amyloidosis 2026

PALO ALTO, Calif., Nov. 11, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for g…

BBIO −0.7% todayRead at source ↗
● GlobeNewsWireNov 9, 2026 · 07:30 ETCOMPANY'S OWN WORDS
BridgeBio to Participate in November and December Investor Conferences

PALO ALTO, Calif., Nov. 09, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for g…

BBIO −0.7% todayRead at source ↗
● GlobeNewsWireNov 6, 2026 · 16:01 ETCOMPANY'S OWN WORDS
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PALO ALTO, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announc…

BBIO −0.7% todayRead at source ↗
● GlobeNewsWireNov 3, 2026 · 07:30 ETCOMPANY'S OWN WORDS
BridgeBio to Present New Acoramidis Data on Heart Failure Events in ATTR-CM at the American Heart Association Scientific Sessions 2026

PALO ALTO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for g…

BBIO −0.7% todayRead at source ↗
● The Motley FoolNov 2, 2026 · 06:45 ETEARNINGS EXPECTED BY FEB 23
Should You Invest $1,000 in BridgeBio Pharma Right Now?

BridgeBio saw revenue climb by 193% year over year in the third quarter. The company's lead therapy is a heart drug, Attruby.…

BBIO −0.7% todayRead at source ↗
● Seeking AlphaOct 29, 2026 · 20:38 ETEARNINGS EXPECTED BY FEB 23
BridgeBio Pharma, Inc. (BBIO) Q3 2026 Earnings Call Transcript

BridgeBio Pharma, Inc. (BBIO) Q3 2026 Earnings Call Transcript…

BBIO −0.7% todayRead at source ↗
● MarketBeatOct 29, 2026 · 20:15 ETEARNINGS EXPECTED BY FEB 23
What BridgeBio Pharma (BBIO) Said on Its Q3 Earnings Call

BridgeBio Pharma NASDAQ: BBIO reported third-quarter revenue growth driven by sales of ATTR cardiomyopathy treatment Attruby and a one-time milestone tied to European partner Bayer's commercialization of Beyonttra. The c…

BBIO −0.7% todayRead at source ↗
● Zacks Investment ResearchOct 29, 2026 · 18:31 ETEARNINGS EXPECTED BY FEB 23
BridgeBio Pharma (BBIO) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for BridgeBio Pharma (BBIO) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and t…

BBIO −0.7% todayRead at source ↗
● Zacks Investment ResearchOct 29, 2026 · 18:11 ETEARNINGS EXPECTED BY FEB 23
BridgeBio Pharma (BBIO) Reports Q3 Loss, Beats Revenue Estimates

BridgeBio Pharma (BBIO) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.6. This compares to a loss of $0.95 per share a year ago.…

BBIO −0.7% todayRead at source ↗
● BenzingaOct 29, 2026 · 17:42 ETEARNINGS EXPECTED BY FEB 23
BridgeBio Pharma Q3 2026 Earnings Call Transcript

BridgeBio Pharma (NASDAQ:BBIO) reported third-quarter financial results on Thursday. The transcript from the company's third-quarter earnings call has been provided below.…

BBIO −0.7% todayRead at source ↗
● GlobeNewsWireOct 29, 2026 · 16:01 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 23
BridgeBio Reports Third Quarter 2026 Financial Results and Corporate Updates

- $353.2 million in total third quarter revenues, primarily comprised of $253.2 million of U.S. Attruby net product revenue (up approximately $31 million sequentially and $145 million year over year). Loss from operation…

BBIO −0.7% todayRead at source ↗
● GlobeNewsWireOct 22, 2026 · 07:30 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 23
BridgeBio to Report Third Quarter 2026 Financial Results and Commercial Updates on October 29, 2026 at 4:30 pm ET

PALO ALTO, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announc…

BBIO −0.7% todayRead at source ↗
● Zacks Investment ResearchOct 20, 2026 · 11:30 ETEARNINGS EXPECTED BY FEB 23
4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch Now

BBIO, NTLA, BIIB and VKTX offer investors potential upside from promising drug pipelines and upcoming FDA decisions and pivotal study results.…

BBIO −0.7% todayRead at source ↗
● GlobeNewsWireOct 16, 2026 · 07:30 ETCOMPANY'S OWN WORDS
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PALO ALTO, Calif., Oct. 16, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announc…

BBIO −0.7% todayRead at source ↗
● Seeking AlphaOct 13, 2026 · 09:00 ETEARNINGS EXPECTED BY FEB 23
BridgeBio: Maintaining 'Strong Buy' Additional Encaleret Data ADH1 And Three Expected FDA Reviews

BridgeBio Pharma maintains a "Strong Buy" rating, driven by robust revenue growth and multiple late-stage pipeline catalysts. The company delivered Q2 2026 net revenues of $243.7M, up from the prior year's $110.6M, outpe…

BBIO −0.7% todayRead at source ↗
● Zacks Investment ResearchOct 7, 2026 · 12:41 ET
FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing

BBIO wins FDA priority review for infigratinib, potentially making it the first approved oral therapy for achondroplasia.…

BBIO −0.7% todayRead at source ↗
● GlobeNewsWireOct 6, 2026 · 16:01 ETCOMPANY'S OWN WORDS
BridgeBio to Present Additional Evidence from the Phase 3 CALIBRATE Trial of Encaleret in ADH1 at the ASBMR 2026 Annual Meeting

PALO ALTO, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for g…

BBIO −0.7% todayRead at source ↗
● GlobeNewsWireOct 6, 2026 · 16:01 ETCOMPANY'S OWN WORDS
BridgeBio to Present New Acoramidis Data, Including Independent Comparative Real-World EHR Data at the HFSA Annual Scientific Meeting 2026

PALO ALTO, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for g…

BBIO −0.7% todayRead at source ↗
● GlobeNewsWireOct 6, 2026 · 07:30 ET
BridgeBio Announces FDA Acceptance and Priority Review of NDA for Oral Infigratinib for Children with Achondroplasia

- Accepted for Priority Review with a PDUFA target action date of February 4, 2027; being granted Priority Review by the FDA underscores the significant unmet need for an oral targeted therapeutic option for children wit…

BBIO −0.7% todayRead at source ↗
● GlobeNewsWireOct 5, 2026 · 16:01 ET
BridgeBio and Community Partners Launch Nationwide ATTR-CM Education Effort Ahead of World Amyloidosis Day

- October 6 YouTube premiere featuring Sway Calloway, Howard “H” White and leading medical and cultural voices anchors community education nationwide…

BBIO −0.7% todayRead at source ↗

Expected by Feb 23. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

NVDA29−0.4%
WDAY4−5.8%
BBW3−2.6%

Article counts from the last market-wide feed page, across every symbol we track and not just BBIO · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.